secwatch.observer — SEC 8-K summary
======================================

Issuer:     Structure Therapeutics Inc. (GPCR)
CIK:        0001888886
Form:       8-K
Filed at:   2023-05-11T23:59:59+00:00
Accession:  0001104659-23-059189
Event type: earnings
Sentiment:  neutral
Materiality: 0.60
Item codes: 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Structure Therapeutics reports Q1 2023 net loss of $18.0M; GSBR-1290 advancing to Phase 2a
--------------------------------------------------------------------------------

- Net loss of $18.0M for Q1 2023, compared to $13.1M in Q1 2022; non-cash stock-based comp $2.5M.
- Cash, cash equivalents and short-term investments totaled $240.9M; expected to fund operations through end of 2025.
- R&D expenses $13.1M (up from $8.5M) driven by GLP-1R franchise advancement and stock-based compensation.
- GSBR-1290 protocol amendment submitted to FDA to transition to Phase 2a proof-of-concept study in T2DM and obesity.
- Topline data from Phase 1b MAD and Phase 2a studies of GSBR-1290 expected in second half 2023.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1888886/000110465923059189/0001104659-23-059189-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1888886/000110465923059189/tm2315251d1_8k.htm
  HTML page:      https://secwatch.observer/filing/0001104659-23-059189

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer